LearnGlossaryMarketStocksSuperinvestorsSign in

ADMA

ADMA Biologics, Inc.

Healthcare · $2.3B market cap

Verdict

We can't put a fair value on ADMA right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-24.3% a year✗
Equity per share growth8.8% a year✗
Sales growth67.6% a year✓
Free cash flow growth—?
Return on invested capital22.4%✓

Follow ADMA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds ADMA. In Q1 2026, 1 trimmed. Who we track

Terry Smith

Fundsmith · as of Q2 2026

$13.8M

1,649,493 shares

Moves in Q1 2026

Trimmed: Terry Smith

About ADMA Biologics, Inc.

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works